Bristol-Myers Squibb (NYSE:BMY) Getting Somewhat Positive Media Coverage, Report Finds
Media headlines about Bristol-Myers Squibb (NYSE:BMY) have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bristol-Myers Squibb earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.688680894371 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Bristol-Myers Squibb Company (BMY) Given a $65.00 Price Target by Cowen and Company Analysts (americanbankingnews.com)
- Watching Historical Performance for Bristol-Myers Squibb Company (NYSE:BMY) – Jonesboro Recorder (jonesbororecorder.com)
- Bristol-Myers Squibb Company (BMY) is at $56.73 per share and NuVasive, Inc. (NUVA) is listed at $66.63 – Stocks Gallery (stocksgallery.com)
- Bristol-Myers Squibb Company (BMY) Stake Trimmed by Main Street Research – Insider Tradings (insidertradings.org)
- Bristol-Myers Squibb Company (NYSE:BMY) Upgraded to “Hold” by BidaskClub (americanbankingnews.com)
Several brokerages have weighed in on BMY. Cowen and Company set a $65.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday. Vetr downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 price target for the company. in a report on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. BidaskClub raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Finally, William Blair reissued an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, June 26th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $62.12.
Shares of Bristol-Myers Squibb (BMY) traded up 1.57% on Monday, reaching $57.62. The company had a trading volume of 5,654,336 shares. The firm has a market capitalization of $94.49 billion, a P/E ratio of 21.04 and a beta of 1.17. Bristol-Myers Squibb has a 52 week low of $46.01 and a 52 week high of $60.45. The company’s 50-day moving average price is $55.83 and its 200 day moving average price is $54.80.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same period last year, the firm earned $0.69 EPS. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. On average, analysts expect that Bristol-Myers Squibb will post $2.97 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were given a dividend of $0.39 per share. The ex-dividend date was Wednesday, July 5th. This represents a $1.56 dividend on an annualized basis and a yield of 2.71%. Bristol-Myers Squibb’s payout ratio is 56.73%.
In related news, Director Theodore R. Samuels II acquired 6,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The stock was bought at an average cost of $55.94 per share, with a total value of $335,640.00. Following the transaction, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.23% of the stock is currently owned by company insiders.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.